As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the health insurance providers ...

Humana (NYSE:HUM) experienced a 3% price increase last week, which may have been influenced by its recent partnership with Mercy to open new primary care clinics for seniors. This expansion addresses ...

Shares of Humana Inc. HUM rose 1.39% to $234.96 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.38% to 6,045.26 and the ...

This was the stock's second consecutive day of gains.

Humacyte markets Symvess for the treatment of extremity vascular trauma. Read why HUMA stock is a Sell but can see its ...

Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

A return of a former CEO and questions about its Medicare Advantage pricing dominate the outlook for this formerly ...

The bill seeks to extend tax breaks, set during Trump’s first term in 2017 and on track to expire at the end of 2025, for ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $307.44, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Humana (NYSE:HUM) and the best and worst ...